Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage biotherapeutics company engaged in developing cancer therapies. The company’s pioneer Selective Inhibitor of Nuclear Export compound technology was developed to address an oncogenesis mechanism of nuclear export dysregulation. XPOVIO is commercialized by the Company in three cancer indications. The company’s candidate pipeline treats endometrial cancer, myelofibrosis, and myelodysplastic disorders.
The price of KPTI stock during the regular trading on February 7, 2022, was $10.2 with an incline of 5.13%. At last check in the premarket on February 8, 2022, the stock dropped by 13.77%.
KPTI: Key Financials
On February 8, 2022, KPTI released its financial results for the fourth quarter of 2021 ended December 31, 2021. Some of the main aspects are mentioned below.
Revenue
Net product revenue in Q4 2021 was $29.8 million compared to $20.2 million for the same quarter in 2020. The revenue was up by 47% over the period of the year. The company missed the estimated revenue target of $31.9 million by $2.1 million.
KPTI: EPS
Net income per share in Q4 2021 was $38.7 million, or $0.51 (basic) and $0.46 (diluted) compared to a basic and diluted net loss of $43.4 million, or $0.59 per share in the same period of 2020. The company’s EPS beat the analysts’ estimate of $0.42 per share.
On February 8, 2022, KPTI updated about optimistic top-line outcomes from the Phase 3 Selinexor studies, assessing its safety and efficacy. The study met its prime endpoint of significant improvement in median PFS. On February 1, 2022, KPTI was informed about the grant of stock options for the acquisition of a total of 124,500 shares of its common stock by the company’s BoDs. The stock option was granted to the new employees as inducement materials in accordance with Nasdaq Listing Rules.
On January 24, 2022, the company reported about the grant of orphan drug designation for eltanexor by the FDA. On January 21, 2022, KPTI updated that the Executive management presented at the Virtual B. Riley Securities Oncology Investor Conference held on January 28, 2022. On January 4, 2022, KPTI informed that its Executive management presented at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022.
Conclusion
KPTI stock outperformed in the last six months by 83%. The company’s latest premarket dip is the result of missed revenue target, as it reported the quarterly results. Although the company beat the estimated EPS and reported the positive topline results of its pipeline candidate, it down-performed in the market. The company’s management is quite hopeful to cover the losses of the company in the upcoming period.
